NIH

Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University

Retrieved on: 
Tuesday, March 19, 2024
Annual report, Attention, CDMO, CHO, CGMP, NIH, Traction, Pharmaceutical industry

DURHAM, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it has been awarded a contract in excess of $1 million with an NIH-funded researcher at a major university.

Key Points: 
  • DURHAM, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it has been awarded a contract in excess of $1 million with an NIH-funded researcher at a major university.
  • The program involves process optimization and development of a therapeutic antibody, which Scorpius will manufacture for preclinical studies.
  • Following process optimization and development, the Company expects to expand the scope of the agreement to include Phase 1 clinical manufacturing.
  • Jeff Wolf, CEO of Scorpius, stated, "Scorpius is excited to begin work with another nationally renowned university.

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Retrieved on: 
Monday, March 18, 2024
Department of Defence, Food and Drug Administration, Burn, Learning, Patient, BVA, Sale, Nature, Statistics, Investment, Note, LVAD, ICU, Duke, Form, Blood volume, NIH, Heart failure, Length of stay, American College, Operation, Hand, Health, Food, Sepsis, Acceleration, Letter, Proxy, Knowledge, Research, Hospital, Acquisition, CLIA, Clinical study design, Family, FDA, Consultant, Annual general meeting, Diagnosis, RCT, Financial statement, Growth, Syncope, Mortality, National Institutes of Health, Nursing care plan, Bangladesh Technical Education Board, Net, Government, Physician, Medicine, Pharmaceutical industry

We have never been more focused on our mission and goals. Every team member at Daxor sees both the remarkable strides the company has made over the past year solidifying its position as the global leader in blood volume measurement technology and the promise of what our rapid expansion means for both the company and the tens of millions of patients whose care we are eager to significantly improve. In every area 2023 and the strong start of 2024 has shown substantial progress for the company -- in revenue growth, new customer acquisitions, increasing utilization of our products by existing customers, next generation systems completed and under Food and Drug Administration (FDA) review, positive clinical studies, new patents granted and pending, successful National Institutes of Health (NIH) grant awards, Department of Defense (DoD) contracts awarded, and further research and development for groundbreaking products set to launch in subsequent fiscal years. I will detail below more in these areas but first wish to review why our company’s mission to commercialize the products that enable optimal patient care is so vital.

Key Points: 
  • Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh.
  • Many of these markers are costly, some are invasive, and none are accurate – in contrast to Daxor’s proven 98% accurate system.
  • Care teams cannot effectively treat what they do not correctly diagnose, so our rapid accurate diagnostic test is a game-changer.
  • Daxor has been reporting as an investment company under the Investment Company Act of 1940 since January 1, 2012.

First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline

Retrieved on: 
Thursday, March 14, 2024
Conference, Webcast, Patient, Common, Fats, GI, Acquisition, First wave, NIH, Gastrointestinal disease, Series, Marketing, Gastroparesis, FDA, Cystic fibrosis, Food, Digestion, Pharmaceutical industry

BOCA RATON, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has acquired ImmunogenX in an all-stock transaction with the combined company focused on advancing a GI pipeline comprised of multiple, late-stage clinical assets, including latiglutenase, a potentially first-in-class, near Phase 3-ready, targeted, oral biotherapeutic for celiac disease. James Sapirstein will continue to serve as Chairman and Chief Executive Officer of First Wave BioPharma with Jack Syage, Ph.D., previously the Chief Executive Officer and Co-Founder of ImmunogenX, assuming the role of President and Chief Operating Officer of First Wave BioPharma. Dr. Syage and Dr. Chaitan Khosla will also join the board of directors of First Wave BioPharma.

Key Points: 
  • Dr. Syage and Dr. Chaitan Khosla will also join the board of directors of First Wave BioPharma.
  • First Wave BioPharma intends to license the commercial rights to latiglutenase in the United States and Canada to a strategic global pharmaceutical company which will commercialize latiglutenase following receipt of marketing approval.
  • First Wave BioPharma will also seek to secure financing commitments from a syndicate of institutional healthcare investors to fund the ongoing development of latiglutenase.
  • First Wave BioPharma will host a conference call and live audio webcast today, March 14, 2024, at 8:30 a.m.

Global Down Syndrome Foundation Applauds House Energy & Commerce Committee for Advancing Legislation to Authorize Down Syndrome Research Program at NIH

Retrieved on: 
Tuesday, March 12, 2024
African Americans, Congress, Down syndrome, Autoimmunity, Investigation, Memory, INCLUDE, Ranking, Patient, Inflammation, Research, Human services, Syndrome, NIH, CO, Legislation, Member of Congress, Bangladesh Technical Education Board, Representative, Hearing, Pharmaceutical industry

7406), which would authorize the INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project at the National Institutes of Health (NIH).

Key Points: 
  • 7406), which would authorize the INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project at the National Institutes of Health (NIH).
  • The legislation will formally authorize a trans-NIH structure to ensure that major crosscutting issues and opportunities within Down syndrome research are identified and allow for multiple institutes to collaborate on a research plan.
  • This will enable institute coordination to plan, fund, and share and disseminate research results that aim to improve health outcomes for those with Down syndrome.
  • To read about the impactful research that the INCLUDE Project has funded visit the NIH Down Syndrome Coordinating Center Website at: https://includedcc.org/.

Velsera and Flywheel Team up to Support Multimodal Imaging Genomics Research

Retrieved on: 
Thursday, April 4, 2024
Other Health, General Health, Radiology, Pharmaceutical, Medical Devices, Technology, Hospitals, Artificial Intelligence, Genetics, Health Technology, Biotechnology, Health, Genomics, Algorithm, MRI, FHIR, Down syndrome, Environment, Investigation, Disease, Patient, Artificial intelligence, AI, PB, NIH, Ecosystem, Privacy, Government, Syndrome, Metadata, Medical imaging

Combining their capabilities, Velsera, Flywheel, and D3b were able to manage, harmonize, and analyze large datasets in a cloud-based platform.

Key Points: 
  • Combining their capabilities, Velsera, Flywheel, and D3b were able to manage, harmonize, and analyze large datasets in a cloud-based platform.
  • The Velsera team created interoperability standards that allow platforms to communicate with each other and make large-scale data access transparent to the user.
  • “Linking our Flywheel Core Platform with Velsera’s CAVATICA platform facilitates an unparalleled ability to perform advanced, multimodal data analysis in a cloud environment,” said Travis Richardson, Chief Strategist at Flywheel.
  • Using data from D3b, teams were able to analyze the combination of extracted imaging features on the Flywheel Core Platform.

Feinstein Institutes Secures $6.1M NIH Grant for Red Cell Disorder Research

Retrieved on: 
Wednesday, April 3, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Diamond, Molecular medicine, Sickle cell disease, Erythropoiesis, Hematology, HMGB1, Cell cycle, Mortality, Doctor of Philosophy, Quality of life, NIH, Diamond–Blackfan anemia, DBA, Credit, Lung, SCD, Medical research, Anemia, Bangladesh Technical Education Board, Multimedia, Conditional sentence, Pharmaceutical industry

To further our understanding and potential treatments of these disorders, The Feinstein Institutes for Medical Research has been awarded a $6.1 million grant from the National Institutes of Health (NIH).

Key Points: 
  • To further our understanding and potential treatments of these disorders, The Feinstein Institutes for Medical Research has been awarded a $6.1 million grant from the National Institutes of Health (NIH).
  • View the full release here: https://www.businesswire.com/news/home/20240403646471/en/
    Dr. Lionel Blanc will lead the new NIH-funded red cell disorders research (Credit: Feinstein Institutes)
    Led by Lionel Blanc, PhD , professor in the Institute of Molecular Medicine at the Feinstein Institutes, the seven-year initiative aims to build off previous research and will shed light on DBA, SCD and anemia.
  • “Understanding red cell blood disorders, how they develop and progress, is essential given their global impact on millions,” said Dr. Blanc.
  • In 2019, he received a $2.5 million grant from the NIH to study treatment for erythropoietic disorders, including DBA.

Juniper Biomedical Secures Seed Funding to Accelerate Growth and Innovation in Pelvic Health Disorders.

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Professional Services, Health, General Health, Women, Venture Capital, Health Technology, Other Science, Medical Devices, Consumer, Science, Biomedicine, Growth, Urinary incontinence, Entrepreneurship, MUI, Patient, Pelvic pain, Incontinence, NIH, Woman, Ecosystem, Medtech, Pharmaceutical industry

The company's first application will offer long-term, precision therapy for patients with mixed urinary incontinence (MUI), which affects nearly 1 in 3 women.

Key Points: 
  • The company's first application will offer long-term, precision therapy for patients with mixed urinary incontinence (MUI), which affects nearly 1 in 3 women.
  • "We believe that Juniper Biomedical has tremendous potential for growth and disruption in pelvic health in the historically underserved patient populations," said Larry Derose, founder of Auroral Holdings.
  • Juniper Biomedical is developing dramatically better therapies for the millions of women and men who suffer in silence from pelvic health conditions like urinary incontinence, bowel incontinence, pelvic pain, sexual dysfunction, and pelvic floor disorders.
  • Our solutions leverage a highly precise, low-power neuromodulation micro-implant that delivers a unique type of therapy to pelvic nerves.

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Retrieved on: 
Tuesday, April 2, 2024
Health, Defense, Infectious Diseases, Pharmaceutical, Contracts, Biotechnology, Ulcer, Paromomycin, Patient, NTD, IND, Metronidazole, Francisella tularensis, Infection, OTCQX, Therapy, Priority review, USD, Risk, Systemic, NIH, Anthrax, Arrangement, World Health Organization, Investigational New Drug, Calendar, Scar, Neglected tropical diseases, Tablet, Public, Research, News, PRV, Acquisition, TSX, Drug development, Population health, Cutaneous leishmaniasis, Canada Business Corporations Act, FDA, Transaction, Government, Growth, Entrepreneurship, Skin infection, Share, Procurement, WHO, Pharmaceutical industry

The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.

Key Points: 
  • The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.
  • Appili licensed the manufacturing and commercialization rights in the U.S. and other selected territories to Saptalis Pharmaceuticals, LLC (“Saptalis”).
  • Appili, in collaboration with Saptalis, continued the product's development, ultimately achieving FDA approval in the United States.
  • With FDA approval, future revenue is expected to be derived from milestone payments and royalties from Saptalis under the license agreement.

Corner Lot Advisors Acquires 8200 Wisconsin Ave

Retrieved on: 
Friday, March 29, 2024
Other Construction & Property, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Urban Planning, Walter Reed Hospital, Walking, Partnership, Purple Line, Yoga, Acquisition, NIH, Wisconsin Avenue, Streetcorner

Corner Lot Advisors, a privately-owned real estate investment firm and operating partner specializing in the acquisition and repositioning of multifamily assets, announced today its purchase of 8200 Wisconsin Avenue, a 245-unit property anchoring the east end of Battery Lane, a major artery in downtown Bethesda, MD.

Key Points: 
  • Corner Lot Advisors, a privately-owned real estate investment firm and operating partner specializing in the acquisition and repositioning of multifamily assets, announced today its purchase of 8200 Wisconsin Avenue, a 245-unit property anchoring the east end of Battery Lane, a major artery in downtown Bethesda, MD.
  • The acquisition offers Corner Lot a unique opportunity to reposition a core Bethesda property and capture growing market demand for larger units in a highly desirable, suburban-urban environment.
  • “For us, 8200 Wisconsin Avenue represented a generational opportunity to acquire and reposition a core multifamily asset in an A+ location,” said Michael (“Chip”) Davis, Managing Principal, Corner Lot Advisors.
  • Corner Lot would also like to thank its brokers on the transaction, specifically Ari Firoozabadi and Kyle Tangney of Greysteel, who helped bring the deal to fruition.

Manifest Technologies Emerges From Stealth With Strategic Investors and Prepares for Next Development Stage of AI-Powered Precision Neuroscience

Retrieved on: 
Thursday, March 28, 2024
Neurology, Biotechnology, Pharmaceutical, Managed Care, Health, Artificial Intelligence, Health Technology, Technology, Entrepreneurship, Psychiatry, Yale University, Associate, Partnership, Myenteric plexus, Patient, CNS, Neuroimaging, Research, DSM-IV codes, Dartmouth College, AI, Psychology, Yale School of Medicine, NIH, Johnson & Johnson, Drug development, CMO, Map

Today, over one billion people on the planet suffer from some form of a brain disorder, with an estimated economic burden of as much as $8.5 trillion per year.

Key Points: 
  • Today, over one billion people on the planet suffer from some form of a brain disorder, with an estimated economic burden of as much as $8.5 trillion per year.
  • There is an urgent unmet need for more rapid and precise development of treatments that are ultimately delivered to the right person at the right time.
  • Recent acquisitions in the neuroscience space highlight the need for tools that can optimize clinical trials and drive more efficient drug development based on precise neural targets.
  • Manifest is actively working with Johnson & Johnson to deploy its solutions across several programs.